id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-309962-phwq8rsf	Vetter, Monica Hagan	Chemotherapy directly followed by PARP inhibition as an alternative to surgery in patients with BRCA- mutated ovarian cancer – a potential management strategy in the era of COVID-19	2020-05-23		.txt	text/plain	724	50	59	title: Chemotherapy directly followed by PARP inhibition as an alternative to surgery in patients with BRCAmutated ovarian cancer – a potential management strategy in the era of COVID-19 Patients with BRCA mutations represent a unique group of EOC patients due to their 57 exquisite platinum-sensitivity and impressive progression-free survival with PARP inhibitor 58 complete clinical response by CA-125 and imaging (cCR) to platinum-based chemotherapy and 60 However, our experiences suggest that patients with BRCA 74 mutations and cCR to primary chemotherapy may be candidates to avoid surgery. This is based on the results of SOLO-1 which demonstrated a hazard ratio for disease 84 progression or death of 0.30 (95% CI, 0.23-0.41) favoring olaparib in patients with advanced 85 stage high-grade EOC with response to primary platinum-based chemotherapy. and BRCA mutations who have complete clinical responses to platinum-based chemotherapy, 89 especially with the excellent outcomes seen in SOLO-1.	./cache/cord-309962-phwq8rsf.txt	./txt/cord-309962-phwq8rsf.txt